Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world studyHui-Zhi Jin, Yu-jing Li, Xin Wang, Zhijun Li, Bin Ma, Lin Niu, Peng Wang, Hai-feng Pan, Si-dong Li, Wei Bao, Guosheng Wang, Xiao-mei Li, Zhu Chen
24 November 2023
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective studyWentian Lu, Ying Zhong, Chenghua Weng, Qing Wang, Mei Tang, Zhichun Liu, Leixi Xue
8 September 2022
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLEDiane L Kamen, Caroline Wallace, Zihai Li, Megan Wyatt, Crystal Paulos, Chungwen Wei, Hongjun Wang, Bethany J Wolf, Paul J Nietert, Gary Gilkeson
12 July 2022
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort studyNan Jiang, Mengtao Li, Hongfeng Zhang, Xinwang Duan, Xiaofeng Li, Yongfei Fang, Hongbin Li, Pingting Yang, Hui Luo, Yanhong Wang, Liying Peng, Jiuliang Zhao, Chanyuan Wu, Qian Wang, Xinping TianSee the full list of authors
3 January 2022
Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional studySafaa A Mahran, Felice Galluccio, Tayseer Mohamed Khedr, Amira Elsonbaty, Abdallah El-Sayed Allam, Alvaro Garcia Martos, Doaa M M Osman, Marco Matucci-Cerinic, Serena Guiducci, Marwa A A Galal
26 July 2021
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)Sarah Dyball, Sophie Collinson, Emily Sutton, Eoghan M McCarthy, Ian N Bruce, Ben Parker
23 July 2021
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trialsRaj Tummala, Gabriel Abreu, Lilia Pineda, M Alex Michaels, Rubana N Kalyani, Richard A Furie, Eric F Morand
17 February 2021
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathwaysThomas Dörner, Yoshiya Tanaka, Michelle A Petri, Josef S Smolen, Daniel J Wallace, Ernst R Dow, Richard E Higgs, Guilherme Rocha, Brenda Crowe, Robert J Benschop, Nicole L Byers, Maria E Silk, Stephanie de Bono, Damiano Fantini, Robert W Hoffman
9 October 2020
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriersCristina Arriens, Teresa Aberle, Fredonna Carthen, Stan Kamp, Aikaterini Thanou, Eliza Chakravarty, Judith A James, Joan T Merrill, Motolani E Ogunsanya
15 March 2020
First use of cenerimod, a selective S1P receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept studyViktoria Hermann, Anastas Batalov, Svetlana Smakotina, Pierre-Eric Juif, Peter Cornelisse
9 November 2019